Anesthetic Management of a Patient With Charcot-Marie-Tooth Disease.
Charcot-Marie-Tooth disease (CMTD) is a hereditary peripheral neuropathy and is characterized by progressive muscle atrophy and motor-sensory disorders in all 4 limbs. Most reports have indicated that major challenges with general anesthetic administration in CMTD patients are the appropriate use of nondepolarizing muscle relaxants and preparation for malignant hyperthermia in neuromuscular disease. Moderate sedation may be associated with the same complications as those of general anesthesia, as well as dysfunction of the autonomic nervous system, reduced perioperative respiratory function, difficulty in positioning, and sensitivity to intravenous anesthetic agents. We decided to use intravenous sedation in a CMTD patient and administered midazolam initially and propofol continuously, with total doses of 1.5 mg and 300 mg, respectively. Anesthesia was completed in 3 hours and 30 minutes without adverse events. We suggest that dental anesthetic treatment with propofol and midazolam may be effective for patients with CMTD.
Department of Anesthesiology and.
Naohiro
N
Ohshita
Marunouchi Dental Clinic, Kagawa, Japan, and.
Saeko
S
Oka
First Department of Oral and Maxillofacial Surgery, Osaka Dental University, Osaka, Japan.
Kaname
K
Tsuji
First Department of Oral and Maxillofacial Surgery, Osaka Dental University, Osaka, Japan.
Hiroaki
H
Yoshida
First Department of Oral and Maxillofacial Surgery, Osaka Dental University, Osaka, Japan.
Shosuke
S
Morita
Department of Anesthesiology and.
Yoshihiro
Y
Momota
Department of Anesthesiology, Tokushima University, Tokushima, Japan.
Yasuo M
YM
Tsutsumi
D000766:Anesthesia, Dental / Q000379:methods*; D000771:Anesthesia, Intravenous / Q000379:methods; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D000779:Anesthetics, Local / Q000008:administration & dosage; D001794:Blood Pressure / Q000502:physiology; D002607:Charcot-Marie-Tooth Disease / Q000150:complications*; D016292:Procedural Sedation / Q000379:methods*; D003758:Dental Implantation, Endosseous / Q000379:methods*; D004837:Epinephrine / Q000008:administration & dosage; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage; D008012:Lidocaine / Q000008:administration & dosage; D008297:Male; D008874:Midazolam / Q000008:administration & dosage; D008875:Middle Aged; D061646:Operative Time; D010100:Oxygen / Q000097:blood; D015742:Propofol / Q000008:administration & dosage; D014662:Vasoconstrictor Agents / Q000008:administration & dosage
D018686:Anesthetics, Intravenous; D000779:Anesthetics, Local; D006993:Hypnotics and Sedatives; D014662:Vasoconstrictor Agents; D008012:Lidocaine; D008874:Midazolam; D010100:Oxygen; D015742:Propofol; D004837:Epinephrine
Charcot-Marie-Tooth disease; Intravenous sedation; Propofol